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Abstract
I In nt tr ro od du uc ct ti io on n: :   Obstructive sleep apnoea syndrome (OSAS) is an important risk
factor in cardiovascular disorders. Although the exact mechanism remains to
be elucidated, the endothelial dysfunction process seems to be implicated. 
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   In order to test this hypothesis, blood circulating levels
of endothelial markers were measured at baseline and 1 year after treatment
with continuous positive airway pressure (CPAP). We studied 37 males using
polysomnography: 20 subjects with OSAS and a 17-subject control group. An
OSAS-validated sleep questionnaire covering the most important cardiovascu-
lar risk factors was applied to all subjects. Furthermore, patients received a com-
plete general physical examination and biochemistry test with lipid profile. The
specific markers measured were intercellular cell adhesion molecule-1 (ICAM-1),
E-selectin, endothelin-1, von Willebrand factor (vWF) and plasminogen activa-
tor inhibitor-1 (PAI-1).
R Re es su ul lt ts s: :   Obstructive sleep apnoea syndrome patients presented higher circu-
lating levels of ICAM-1, endothelin-1 and PAI-1 than the control group. On the
other hand, no differences were found in E-selectin and vWF. After 1 year of
CPAP treatment, there was a significant decrease in circulating levels of ICAM-1
and PAI-1. On the other hand, no differences were found in endothelin-1, 
E-selectin and vWF. 
C Co on nc cl lu us si io on ns s: :   Obstructive sleep apnoea syndrome is associated with elevated
levels of ICAM-1 and PAI-1 and these levels normalize after treatment with CPAP.
K Ke ey y    w wo or rd ds s: :   obstructive  sleep  apnoea  syndrome,  intercellular  cell  adhesion 
molecule-1, E-selectin, endothelin-1, plasminogen activator inhibitor-1.
Introduction
Obstructive sleep apnoea syndrome (OSAS) is a respiratory disorder
characterized by recurrent airflow obstruction caused by total or partial
collapse of the upper airway. Obstructive sleep apnoea syndrome is a com-
mon disorder [1], with important consequences such as deterioration of
quality of life [2] and more frequent automobile accidents [3]. Obstructive
sleep apnoea syndrome has been associated with hypertension and car-
diovascular disease [4] and a number of studies have shown that this car-
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diovascular risk decreases after continuous posi-
tive airway pressure (CPAP) treatment [5, 6].
Increased sympathetic activity and hypoxia asso-
ciated with apnoeic episodes has been proposed
as a possible mechanism to explain the association
between OSAS and cardiovascular disease [7]. Con-
tinuous positive airway pressure treatment may
lower cardiovascular risk by reducing sympathetic
nerve activity, ambulatory blood pressure and arte-
rial stiffness and by increasing sensitivity of the
arterial baroreflex [8, 9]. 
Obstructive sleep apnoea syndrome-induced
hypoxic stress increases circulating inflammatory
mediators leading to cardiovascular lesions [10, 11],
which in turn may lead to endothelial dysfunction.
Endothelial dysfunction is an early marker of vas-
cular abnormality preceding clinically overt cardio-
vascular disease [12]. It is known that endothelial
dysfunction identified in the peripheral vasculature
strongly predicts coronary disease [13]. A number
of studies involving OSAS patients indicate an asso-
ciated endothelial dysfunction [14, 15] that improves
after CPAP [16, 17]. 
An imbalance of the coagulation/fibrinolysis axis
may also exist. Hypercoagulability resulting from
increased coagulation or inhibited fibrinolysis is
associated with an increased risk of atherothrom-
botic disease and cardiovascular disease [18, 19].
A prothrombotic state has been associated with
increased risk of coronary artery disease [20] and
is a possible link between OSAS and cardiovascu-
lar disease [21]. Although most of the above-men-
tioned OSAS-related physiopathological conse-
quences return to normal after CPAP treatment, the
results reported in the literature have not been con-
sistent. The reason may be that these studies do
not exclude other cardiovascular risk factors and
that their analysis of markers is too limited. 
The aim of the present study was to measure
circulating ICAM-1, E-selectin, endothelin-1, von
Willebrand factor (vWF) and plasminogen activator
inhibitor-1 (PAI-1) in OSAS patients before CPAP
treatment at 1-year follow-up. 
Material and methods
S Su ub bj je ec ct ts s
The present study included 20 male subjects, 
33 to 64 years of age (mean of 49.9 ±8.9 years),
with a mean apnoea-hypopnoea index (AHI) of 45.2
±26.2 and body mass index (BMI) of 29.9 ±4.6
kg/m2, diagnosed with OSAS after performing
polysomnography studies. A control group made up
of 17 male subjects from the general population
was also included. Exclusion criteria were previous
treatment for OSAS, chronic obstructive lung dis-
ease, vascular disease, history of hypertension, dia-
betes mellitus, and chronic renal illness.
The Review Board on Human Studies at our insti-
tution approved the protocol, and each patient gave
his or her informed consent to participate in the
study.
I In nt te er rv ve en nt ti io on ns s
An OSAS-validated sleep questionnaire covering
the most important cardiovascular risk factors was
applied  to  all  subjects.  Furthermore,  patients
received a complete general physical examination,
biochemistry test with lipid profile and polysomno-
graphic tests. 
Polysomnographies were carried out in our Sleep
Unit usually from midnight to 8 a.m. This technique
consisted of continuous monitoring using a poly-
graph (Ultrasom Network, Nicolet, Madison, Wi,
USA) and included electroencephalogram, electro-
oculogram, chin electromyogram, airflow, electro-
cardiogram and measurement of chest wall move-
ment. The polysomnographic register was analysed
in periods of 30 s and during stages 1, 2, 3, 4 and
REM according to standard criteria. 
Apnoea was defined as the absence of airflow
for more than 10 s, and hypopnoea as 50% reduc-
tion of respiratory flow for at least 10 s resulting in
an arousal or a decrease of 4% in the oxygen sat-
uration of haemoglobin 
The average apnoea-hypopnoea index (AHI) was
calculated in hourly samples of sleep. In this study
an AHI ≥ 10 was considered as diagnostic of OSAS.
If the subject had less than 3 hours of total sleep,
the sleep study was repeated. 
The optimal CPAP level was determined in the
laboratory during the study. It was defined as the
combination of the lowest pressure, lowest num-
ber of respiratory events and arousals, and the
highest sleep efficiency.
E En nd do ot th he el li ia al l   m ma ar rk ke er rs s
Whole blood was obtained by venipuncture in all
subjects  between  8  a.m.  and  10  a.m.  after
polysomnographic study. 
A total of 5 endothelial dysfunction markers
were measured: ICAM-1, E-selectin, endothelin-1,
vWF, PAI-1. The blood samples were centrifuged at
1000 g for 10 min, and serum/plasma was frozen
and stored at –20°C. 
Commercially available enzyme-linked immuno  -
sorbent assay (ELISA) methods were used to deter-
mine serum levels of ICAM-1 and soluble E-selectin
(R&D Systems, Minneapolis, USA), EDTA-plasma
levels of endothelin-1 (Biomedica, Wien, Austria),
and citrated plasma levels of vWf and PAI-1 (Diag-
nostica Stago, Asnieres, France).
The mean minimal detectable level was deter-
mined by adding two standard deviations to the
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replicates and calculating the corresponding con-
centrations. 
F Fo ol ll lo ow w- -u up p   p pr ro ot to oc co ol l   
Serum/plasma levels of endothelial markers
were measured at baseline and 1 year after CPAP
treatment. Patient interviews were conducted by
a study-team member who was not aware of the
patient’s AHI status and did not participate in any
other aspects of clinical management. No inter-
ventions other than CPAP therapy were introduced
at follow-up. Referring physicians were permitted
to modify general medical therapy as required. All
patients received standardized instructions by Sleep
Center staff and by a home health care provider at
the start of CPAP treatment. Patients were reviewed
at the Sleep Clinic at 1, 6, and 12 months or when
any problem with the CPAP device or mask fit was
encountered. In addition, patients were reviewed
every 2 months by a home health care provider. 
C Co on nt ti in nu uo ou us s   p po os si it ti iv ve e   a ai ir rw wa ay y   p pr re es ss su ur re e   
c co om mp pl li ia an nc ce e
The total time that CPAP units were switched on
was logged using the unit time clock. A home
health care provider registered these compliance
measures. Each time the patient was visited, the
number of hours logged on the meter was record-
ed and the CPAP device was given a maintenance
check. 
C Co on nt ti in nu uo ou us s   p po os si it ti iv ve e   a ai ir rw wa ay y   p pr re es ss su ur re e   
s sa at ti is sf fa ac ct ti io on n   s sc ca al le e
At 12-month follow-up, patients were asked to
rank CPAP treatment on a scale from 0 (‘‘no effect
at all’’) to 10 (‘‘complete relief of symptoms’’).
D Da at ta a   a an na al ly ys si is s   a an nd d   m me ea as su ur re em me en nt ts s
Continuous variables are expressed as mean ±
standard deviation, or as median (percentile 25, per-
centile 75). The t-test, two tailed for paired sam-
ples, was applied to test differences pre- and post-
treatment; non-normally distributed variables were
compared using Wilcoxon rank sum test for paired
data.  Statistical  significance  was  accepted  at 
p < 0.05. All analyses were developed using the Sta-
tistical Package for Social Sciences (SPSS, version
15.0; SPSS Inc. Chicago, IL, USA).
Results
Baseline clinical characteristics of patients and
control subjects were similar for age, body mass
index (BMI), smoking habit and blood pressure
(Table I). 
After 12 months of nasal CPAP treatment, 82%
of patients reported that they had used nasal CPAP
every day for more than 5 h per night. The CPAP
titration pressure ranged from 5 cm H2O to 14 cm
H2O (mean = 7.8 ±1.51 cm H2O). On average, CPAP
was used for 5.24 ±2.75 h per night. Patients self-
reported a level of satisfaction of 7.48 ±1.90 points
after the CPAP treatment.
Table II describes circulating endothelial mark-
ers. Levels of ICAM-1, E-selectin and endothelin-1
were significantly elevated in OSAS patients as
compared to controls. After treatment we can see
a significant decrease in ICAM-1 and PAI, but not in
endothelin, E-selectin, or vWF.
Discussion
The present study demonstrates that endothe-
lial dysfunction, represented by changes in certain
circulating endothelial markers, is present in OSAS.
We found that treating OSAS patients with CPAP
V Va ar ri ia ab bl le e C Co on nt tr ro ol l   g gr ro ou up p O OS SA AS S   g gr ro ou up p V Va al lu ue e   o of f   p p
( (n n = =   1 18 8) ) ( (n n = =   2 20 0) )
Age [year] 44.1 (14.2) 50.1 (8.9) 0.12
Smokers, n (%) 5 (27) 8 (40) 0.364
BMI [kg/m2] 27.6 (3.1) 29.9 (4.6) 0.078
SBP [mmHg] 124 (7.3) 128 (11) 0.156
DBP [mmHg] 79.7 (11.4) 78.5 (10.5) 0.734
T Ta ab bl le e   I I. . Cardiovascular risk factors in control and
OSAS groups
BMI – body mass index, SBP – systolic blood pressure, DBP – diastolic
blood pressure, data are expressed as mean (SD)
V Va ar ri ia ab bl le e C Co on nt tr ro ol l   g gr ro ou up p   ( (n n = =   1 18 8) ) O OS SA AS S   g gr ro ou up p   ( (n n = =   2 20 0) ) V Va al lu ue e   o of f   p p A Af ft te er r   C CP PA AP P   ( (n n = =   2 20 0) ) V Va al lu ue e   o of f   p p
ICAM-1 [ng/ml] 218 (190, 255) 261 (200, 294) 0.050 229 (182, 270) 0.022
E-selectin [ng/ml] 54 (45, 63) 66 (48, 90) 0.143 72 (42, 93) 0.234
Endothelin [fmol/ml] 0.2 (0.12, 0.30) 0.35 (0.26, 0.45) 0.003 0.35 (0.26, 0.40) 0.722
vWF [%] 76 (63, 91) 83 (65, 100) 0.411 79 (65, 101) 0.616
PAI-1 [ng/ml] 30 (18, 45) 52 (24, 72) 0.027 37 (12, 53) 0.020
T Ta ab bl le e   I II I. . Plasma levels of vascular endothelial markers in control and OSAS group at baseline and after 1 year of
CPAP treatment
BMI – body mass index, AHI – apnoea-hypopnoea index, ICAM – intercellular adhesion molecule 1, vWF – von Willebrand factor, PAI – plas-
minogen activator inhibitor-1, data are medians and 25th-75th percentile ranges (within parentheses)1026 Arch Med Sci 6, December / 2011
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reduced levels of ICAM-1 and PAI-1. On the other
hand, no changes were found in endothelin, Von
Willebrand factor and E-selectin.
The intact endothelium regulates vascular tone
and repair capacity, maintaining proinflammatory,
anti-inflammatory, and coagulation homeostasis.
Endothelial dysfunction is characterised by an
increase in vasoconstrictive substances, such as
endothelin, and activation of adhesion molecules,
such as ICAM-1 and E-selectin [22]. Alteration of
these homeostatic pathways results in endothelial
dysfunction before structural changes in the vas-
culature.
The association of endothelial function with OSAS
observed in our study is consistent with other stud-
ies showing an association between OSAS and oth-
er markers of endothelial dysfunction, such as cir-
culating levels of adhesion molecules [23], and
vascular endothelial growth factor [24]. Furthermore,
these changes improve after CPAP therapy [23, 24].
In a previous study, we found that OSAS patients
compared to a control group had increased levels
of ICAM-1, and that this could be due to OSAS-
induced hypoxia [25]. Low oxygen tension is a trig-
ger for activation of polymorphonuclear neutrophils,
which adhere to the endothelium. El-Solh et al.
observed that both were significantly correlated
with the oxygen desaturation index, thus suggest-
ing that expression of adhesion molecules might
be related to the intermittent hypoxia observed dur-
ing sleep [26]. In fact, in vitro studies involving per-
fused cell cultures have shown that hypoxia/reoxy-
genation  causes  an  increase  in  the  levels  of
adhesion molecules [27].
The hypoxia, hypercapnia, and arterial pressure
surges accompanying obstructive apnoeic events
may serve as potent stimuli for the release of
vasoactive  substances  and  for  impairment  of
endothelial function [28, 29]. 
A variety of findings support the existence of
a relation between hypercoagulability, OSAS and
cardiovascular disease. Firstly, patients with OSAS
present higher plasma levels of several procoagu-
lant factors such as fibrinogen [30], platelet activi-
ty [31], and PAI-1 [32, 33]. Secondly, increased 
D-dimer levels in untreated OSAS have been cor-
related  with  severity  of  nocturnal  hypoxemia, 
characteristic of OSAS [34]. Thirdly, sleep fragmen-
tation and sleep efficiency data have been associ-
ated with increased levels of vWF and soluble tis-
sue factor (sTF), two markers of a prothrombotic
state [35]. 
In OSAS, surges in sympathetic nervous system
activity associated with apnoeic events have also
been related to anti-fibrinolytic activity reflected by
elevations of PAI-1 [21, 36]. In a previous study, we
also found that patients with OSAS presented sig-
nificantly higher circulating levels of PAI-1, and the
difference was even more marked in patients with
both OSAS and hypertension [32]. In the current
study, treatment with CPAP decrease blood levels
of PAI-1.
Among the most important vasoconstrictive sub-
stances is endothelin-1, a peptide hormone secret-
ed under the influence of hypoxia [37, 38]. Howev-
er,  the  evidence  for  increased  production  of
vasoconstrictive substances such as endothelin-1
in patients with OSAS is inconsistent. Several stud-
ies have reported higher endothelin-1 levels in OSAS
patients [25, 39, 40]; however, Grimpen reports con-
flicting findings [41]. This divergence might be
explained by differences in study design. The groups
studied by Phillips et al. [39] and Saarelainen and
Hasan [40] had more severe disease and thus
underwent more severe oxygen desaturations that
acted as a trigger for endothelin-1 secretion. Gjo /rup
showed that hypertensive OSAS patients had greater
nocturnal and diurnal endothelin-1 plasma levels 
than healthy controls, suggesting that OSAS does
not affect plasma endothelin-1 levels in the absence
of coexistent cardiovascular diseases [42, 43]. 
The inconsistency of the above endothelin-1 lev-
els likely reflects the predominantly abluminal
release of endothelin. Using rat models of arterial
hypertension, several authors have reported ele-
vated vascular production of endothelin-1, while cir-
culating levels remained similar to controls [44, 45].
This  demonstrates  that  circulating  levels  of
endothelin-1 do not exclude elevated vascular pro-
duction in OSAS. Our findings indicate that the con-
trol of apnoeas through CPAP treatment did not
modify initial levels of endothelin.
Certain limitations in the present study need to
be taken into consideration. Firstly, the measure-
ments of circulating adhesion molecules were
based on the assumption that the number of cir-
culating adhesion molecules reflects the number of
cell surface adhesion molecules. Secondly, blood
samples were obtained only in the morning, which
may have affected random variability because oscil-
lations during the day were not taken into account. 
In conclusion, as a follow-up to our previous find-
ings regarding the increased levels of adhesion mol-
ecules and PAI-1 associated with OSAS, here we
demonstrate that levels of these markers return to
normal with long-term CPAP treatment.
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